Disease-modifying antirheumatic drugs.
Brasington
Richard
R
Washington University School of Medicine, St. Louis, Missouri 63110, USA. richard.brasington@sbcglobal.net
D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001379:Azathioprine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000494:pharmacology / Q000627:therapeutic use; D007555:Isoxazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077339:Leflunomide; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use; D012460:Sulfasalazine / Q000494:pharmacology / Q000627:therapeutic use
D018501:Antirheumatic Agents; D007555:Isoxazoles; D012460:Sulfasalazine; D006886:Hydroxychloroquine; D000077339:Leflunomide; D001379:Azathioprine; D008727:Methotrexate